FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection By Ogkologos - February 7, 2025 791 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-67T study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Talk Cancer: How to have conversations that could save lives April 13, 2021 FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia September 3, 2021 The Doctor Will See You Now…On the Screen July 2, 2020 Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... December 19, 2024 Load more HOT NEWS Honoring our Labor Colorectal Cancer Screening: The Silver Lining Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer... Aided by Community Health Workers, People with Advanced Cancer Need Fewer...
